From Patterson's 19 June 09 Research Note (page 10):
A study by Czerepak et Ryser established a biotech failure rate of 74% (although we would make the
observation that aspects of the treatment have been significantly de-risked, as a result of the current
widespread use of Artmether in tablet form). This implies a risk adjusted value for Eastland® of $0.26.
If phase III trials are successful and after other appropriate submissions (below uses FDA approvals
as a proxy albeit not relevant for ArtiMistTM), then Eastland® valuation would rise to ~$1.50 on a derisked
commercialised basis.
- Forums
- ASX - By Stock
- EMS
- pre trial npv of 26c
pre trial npv of 26c
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EMS (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.1¢ |
Change
0.001(5.00%) |
Mkt cap ! $2.387M |
Open | High | Low | Value | Volume |
2.1¢ | 2.1¢ | 2.1¢ | $336 | 16K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 486396 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.2¢ | 112118 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 486396 | 0.019 |
2 | 360248 | 0.018 |
3 | 315000 | 0.017 |
1 | 29999 | 0.014 |
1 | 41670 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.022 | 112118 | 1 |
0.025 | 231124 | 1 |
0.030 | 78062 | 4 |
0.031 | 294547 | 1 |
0.032 | 138055 | 1 |
Last trade - 13.04pm 11/10/2024 (20 minute delay) ? |
Featured News
EMS (ASX) Chart |